Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.37), $0.01 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.79 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal